New Edge Advisors, LLC Exelixis, Inc. Transaction History

New Edge Advisors, LLC

$18.3 Billion
Q2 2025

A detailed history of New Edge Advisors, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 22,526 shares of EXEL stock, worth $865,899. This represents 0.01% of its overall portfolio holdings.

Number of Shares

22,526

Previous 18,258 23.38%

Holding current value

$865,899

Previous $674,000 47.18%

% of portfolio

0.01%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$34.13 - $46.26 $145,666 - $197,437	4,268 Added 23.38%	22,526 $992,000
Q1 2025 May 15, 2025	SELL	$32.38 - $39.16 $312,467 - $377,893	-9,650 Reduced 34.58%	18,258 $674,000
Q4 2024 Feb 13, 2025	BUY	$25.39 - $36.46 $377,219 - $541,686	14,857 Added 113.84%	27,908 $929,000
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $152,073 - $191,130	-6,925 Reduced 34.67%	13,051 $338,000
Q2 2024 Aug 15, 2024	SELL	$20.34 - $23.73 $197,786 - $230,750	-9,724 Reduced 32.74%	19,976 $448,000
Q1 2024 May 14, 2024	BUY	$20.17 - $23.93 $32,856 - $38,981	1,629 Added 5.8%	29,700 $704,000
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $167,552 - $210,027	8,704 Added 44.94%	28,071 $673,000
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $206,538 - $232,796	11,367 Added 142.09%	19,367 $370,000
Q1 2023 May 12, 2023	SELL	$16.3 - $19.41 $10,725 - $12,771	-658 Reduced 7.6%	8,000 $155,000
Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $40,631 - $47,231	-2,716 Reduced 23.88%	8,658 $138,000
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $178,344 - $253,298	11,374 New	11,374 $178,000
Q1 2021 Apr 26, 2021	SELL	$20.53 - $25.22 $285,202 - $350,356	-13,892 Closed	0 $0
Q4 2020 Jan 27, 2021	BUY	$18.39 - $24.8 $50,590 - $68,224	2,751 Added 24.69%	13,892 $279,000
Q3 2020 Nov 03, 2020	SELL	$20.67 - $26.94 $149,650 - $195,045	-7,240 Reduced 39.39%	11,141 $272,000
Q2 2020 Jul 29, 2020	SELL	$16.46 - $27.42 $66,498 - $110,776	-4,040 Reduced 18.02%	18,381 $436,000
Q1 2020 May 04, 2020	BUY	$14.46 - $21.8 $52,648 - $79,373	3,641 Added 19.39%	22,421 $386,000
Q4 2019 Jan 31, 2020	BUY	$15.15 - $18.89 $8,923 - $11,126	589 Added 3.24%	18,780 $330,000
Q3 2019 Nov 06, 2019	SELL	$17.68 - $22.65 $1,785 - $2,287	-101 Reduced 0.55%	18,191 $322,000
Q2 2019 Aug 05, 2019	BUY	$18.93 - $24.75 $795 - $1,039	42 Added 0.23%	18,292 $391,000
Q1 2019 May 14, 2019	SELL	$19.6 - $24.76 $1.24 Million - $1.57 Million	-63,430 Reduced 77.66%	18,250 $434,000
Q1 2019 May 09, 2019	BUY	$19.6 - $24.76 $897,268 - $1.13 Million	45,779 Added 127.51%	81,680 $1.22 Million
Q4 2018 Jan 29, 2019	BUY	$13.65 - $21.8 $39,598 - $63,241	2,901 Added 8.79%	35,901 $706,000
Q1 2018 May 11, 2018	BUY	$22.15 - $31.89 $66,450 - $95,670	3,000 Added 10.0%	33,000 $709,000
Q2 2017 Aug 16, 2017	BUY	N/A	30,000	30,000 $0

Others Institutions Holding EXEL

# of Institutions

688

Shares Held

260M

Call Options Held

1.41M

Put Options Held

1.55M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $12.4B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.

Account

New Edge Advisors, LLC Exelixis, Inc. Transaction History